back to cluster viewer
cluster path 1110100001111010
55 words, 10,524 tokens
freq alpha suffix
Words in frequency order
1 | expected | 8,494
|
2 | anticipated | 1,268
|
3 | projected | 630
|
4 | inseparable | 24
|
5 | expectable | 10
|
6 | transferrable | 6
|
7 | nonirritating | 5
|
8 | unforeseeable | 5
|
9 | 1/10,000 | 4
|
10 | 5000mg/kg | 4
|
11 | ergonomically | 4
|
12 | 2-to-1 | 3
|
13 | bushi | 3
|
14 | emmer-1 | 3
|
15 | hrs-1990 | 3
|
16 | immaterial | 3
|
17 | nonvictims | 3
|
18 | ptk787 | 3
|
19 | skyrocketing | 3
|
20 | bi-component | 2
|
21 | drawn.no | 2
|
22 | followed.the | 2
|
23 | needed.the | 2
|
24 | non-cirrhotics | 2
|
25 | over-reported | 2
|
26 | photoisomerized | 2
|
27 | proplastids | 2
|
28 | re-sampled | 2
|
29 | repaid | 2
|
30 | 0-045 | 1
|
31 | 1/35th | 1
|
32 | care-as-usual-group | 1
|
33 | enrollment-based | 1
|
34 | excessiveness | 1
|
35 | fda-verified | 1
|
36 | haploidy | 1
|
37 | low.six | 1
|
38 | mortality.primary | 1
|
39 | non-dermatologists | 1
|
40 | non-revascularizable | 1
|
41 | nonmovers | 1
|
42 | pd/ac | 1
|
43 | placebo+amph | 1
|
44 | priority-reviewed | 1
|
45 | proselfs-even | 1
|
46 | rare.improved | 1
|
47 | slide-intensive | 1
|
48 | small-12 | 1
|
49 | studied.the | 1
|
50 | testedin | 1
|
51 | top-to-bottom | 1
|
52 | ultraflo | 1
|
53 | zero-no | 1
|
54 | γ-z | 1
|
55 | ∼11kbin | 1
|
Words in alphabetical order
1 | 0-045 | 1
|
2 | 1/10,000 | 4
|
3 | 1/35th | 1
|
4 | 2-to-1 | 3
|
5 | 5000mg/kg | 4
|
6 | anticipated | 1,268
|
7 | bi-component | 2
|
8 | bushi | 3
|
9 | care-as-usual-group | 1
|
10 | drawn.no | 2
|
11 | emmer-1 | 3
|
12 | enrollment-based | 1
|
13 | ergonomically | 4
|
14 | excessiveness | 1
|
15 | expectable | 10
|
16 | expected | 8,494
|
17 | fda-verified | 1
|
18 | followed.the | 2
|
19 | haploidy | 1
|
20 | hrs-1990 | 3
|
21 | immaterial | 3
|
22 | inseparable | 24
|
23 | low.six | 1
|
24 | mortality.primary | 1
|
25 | needed.the | 2
|
26 | non-cirrhotics | 2
|
27 | non-dermatologists | 1
|
28 | non-revascularizable | 1
|
29 | nonirritating | 5
|
30 | nonmovers | 1
|
31 | nonvictims | 3
|
32 | over-reported | 2
|
33 | pd/ac | 1
|
34 | photoisomerized | 2
|
35 | placebo+amph | 1
|
36 | priority-reviewed | 1
|
37 | projected | 630
|
38 | proplastids | 2
|
39 | proselfs-even | 1
|
40 | ptk787 | 3
|
41 | rare.improved | 1
|
42 | re-sampled | 2
|
43 | repaid | 2
|
44 | skyrocketing | 3
|
45 | slide-intensive | 1
|
46 | small-12 | 1
|
47 | studied.the | 1
|
48 | testedin | 1
|
49 | top-to-bottom | 1
|
50 | transferrable | 6
|
51 | ultraflo | 1
|
52 | unforeseeable | 5
|
53 | zero-no | 1
|
54 | γ-z | 1
|
55 | ∼11kbin | 1
|
Words in suffix order
1 | 1/10,000 | 4
|
2 | hrs-1990 | 3
|
3 | 2-to-1 | 3
|
4 | emmer-1 | 3
|
5 | small-12 | 1
|
6 | 0-045 | 1
|
7 | ptk787 | 3
|
8 | pd/ac | 1
|
9 | fda-verified | 1
|
10 | re-sampled | 2
|
11 | enrollment-based | 1
|
12 | anticipated | 1,268
|
13 | projected | 630
|
14 | expected | 8,494
|
15 | over-reported | 2
|
16 | rare.improved | 1
|
17 | priority-reviewed | 1
|
18 | photoisomerized | 2
|
19 | repaid | 2
|
20 | needed.the | 2
|
21 | studied.the | 1
|
22 | followed.the | 2
|
23 | unforeseeable | 5
|
24 | inseparable | 24
|
25 | transferrable | 6
|
26 | expectable | 10
|
27 | non-revascularizable | 1
|
28 | slide-intensive | 1
|
29 | 5000mg/kg | 4
|
30 | nonirritating | 5
|
31 | skyrocketing | 3
|
32 | placebo+amph | 1
|
33 | 1/35th | 1
|
34 | bushi | 3
|
35 | immaterial | 3
|
36 | top-to-bottom | 1
|
37 | proselfs-even | 1
|
38 | ∼11kbin | 1
|
39 | testedin | 1
|
40 | ultraflo | 1
|
41 | zero-no | 1
|
42 | drawn.no | 2
|
43 | care-as-usual-group | 1
|
44 | non-cirrhotics | 2
|
45 | proplastids | 2
|
46 | nonvictims | 3
|
47 | nonmovers | 1
|
48 | excessiveness | 1
|
49 | non-dermatologists | 1
|
50 | bi-component | 2
|
51 | low.six | 1
|
52 | haploidy | 1
|
53 | ergonomically | 4
|
54 | mortality.primary | 1
|
55 | γ-z | 1
|